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Summary
Although studies have identified hundreds of loci associated with human traits and diseases, 
pinpointing causal alleles remains difficult, particularly for non-coding variants. To address this 
challenge, we adapted the massively parallel reporter assay (MPRA) to identify variants that 
directly modulate gene expression. We applied it to 32,373 variants from 3,642 cis-expression 
quantitative trait loci and control regions. Detection by MPRA was strongly correlated with 
measures of regulatory function. We demonstrate MPRA's capabilities for pinpointing causal 
alleles, using it to identify 842 variants showing differential expression between alleles, including 
53 well-annotated variants associated with diseases and traits. We investigated one in detail, a risk 
allele for ankylosing spondylitis, and provide direct evidence of a non-coding variant that alters 
expression of the prostaglandin EP4 receptor. These results create a resource of concrete leads and 
illustrate the promise of this approach for comprehensively interrogating how non-coding 
polymorphism shapes human biology.
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 Introduction
The genomic era has enormously increased our knowledge of human genetic variation, but 
our understanding of the functional consequences of that variation has not kept pace (Cooper 
and Shendure, 2011). While genome-wide association studies (GWAS) and whole genome 
scans for natural selection have identified numerous loci linked to human traits and diseases, 
correlation between nearby polymorphisms (linkage disequilibrium, or LD) within 
individual associations often leaves dozens to hundreds of potential causal variants to be 
interrogated (Grossman et al., 2013; Schaub et al., 2012). Mounting evidence suggests that 
at the majority of these loci, the causal variant(s) is a non-coding regulatory change rather 
than an amino acid substitution (Farh et al., 2015). Indeed, regulatory changes drive some of 
the best-understood examples of phenotypic diversity and adaptive evolution (Claussnitzer et 
al., 2015; Musunuru et al., 2010; Tishkoff et al., 2007). Therefore, it is critical that we be 
able to test whether a variant affects gene regulation.
Current approaches for measuring a variant's effect on gene expression fall into two 
categories, each with its own limitation. Indirect methods, such as whole-genome epigenetic 
assays, can only identify the broader regulatory state of a region, not necessarily the effect of 
a particular variant (Andersson et al., 2014; Consortium; Kasowski et al., 2013; McVicker et 
al., 2013). Direct methods, ones that measure the impact of individual alleles in an episomal 
or native context on gene expression, are currently low throughput and require substantial 
resources for comprehensive evaluation of a region.
We adopted the MPRA assay as a solution and modified it so that we could carry out large-
scale, sensitive and direct testing of potential regulatory variants. This assay is based upon 
the well-established reporter gene assay, in which a vector containing a reporter gene (e.g. 
luciferase or green fluorescent protein [GFP]), a promoter and a potential regulatory 
sequence is inserted into a plasmid, which is transfected into a cell; sequences that regulate 
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gene expression then alter the amount of luciferase/GFP expressed (Arnold et al., 2013; 
Melnikov et al., 2012; Ow et al., 1986; Patwardhan et al., 2012; Vockley et al., 2015; 
Kwasnieski et al., 2014). Through the use of unique barcodes in the 3′ untranslated region 
(UTR) of the reporter to differentiate expression of individual oligos, MPRA can test many 
different sequences simultaneously, and it has been shown to reproducibly detect segments 
of the genome that change expression levels (Kheradpour et al., 2013; Mogno et al., 2013). 
We aimed to incorporate single nucleotide and small insertion/deletion polymorphisms, 
(referred to below as single nucleotide variants or SNVs), into these assays, to see if we 
could detect subtle differences in how each allele drives expression. Because we use only a 
minimal promoter, with very low baseline expression, in this iteration of the assay, we intend 
it primarily as a test of regulatory sequence that increases (i.e. enhancers and promoters), 
rather than decreases, expression; the latter will be difficult to detect, since baseline 
expression is already low.
Ideally, one would test the assay for sensitivity and specificity by applying it to a set of 
‘gold-standard’ variants previously identified as expression quantitative trait loci (eQTLs) 
that act on enhancer and promoter elements. However, there is a dearth of such known 
variants. As the best available alternative, we studied a set of thousands of candidate eQTL 
variants in regions associated with differential gene expression in the population. There are 
important considerations in interpreting the results of such a test. First, we test multiple 
candidate variants (sometimes dozens) within each eQTL region that are in LD with one 
another. We generally expect that at most one of these variants will be causal, and sometimes 
the true causal variant will not appear in the set, because the degree of LD falls below the 
cutoff used for inclusion. For these reasons only a minority of the variants tested are 
expected to give a signal in the MPRA assay. Conservative estimates suggest that in 34-41% 
of eQTL peaks (dependent on the population tested), the causal variant will be the top 
associated allele. Second, only a subset of the true variants responsible for eQTLs (23-64%, 
according to recent estimates) will act on enhancers or promoters, which are the functional 
classes that will be detected in the MPRA assay (Farh et al., 2015; Gymrek et al., 2015; 
Lappalainen et al., 2013). Variants that work by other processes, such as microsatellites or 
post-transcriptional regulation, would not be expected to score.
Because we expect only a minority (8-26% based on the prior estimates) of the variants in 
our test set to score by MPRA, we must evaluate the assay by comparison with the 
performance on control sets of common polymorphisms. We used two control sets: the first 
chosen randomly from the genome, and the second containing variants near but not 
associated with eQTL variants.
We estimated the specificity, sensitivity and reproducibility of MPRA to localize causal 
alleles within large genomic loci linked to variation in gene expression. In addition, we 
comprehensively interrogated GWAS loci that overlap with eQTLs to identify and 
characterize potential regulatory variants underlying human diseases and traits.
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 Results
 Adapting MPRA to Test ∼30k Candidate Variants
We modified MPRA to increase its throughput while also improving its reproducibility and 
sensitivity (Figure 1, Experimental Procedures); the latter is crucial, since we aim not merely 
to find genetic elements that regulate genes, but to detect differences in regulation caused by 
single variants within those elements. To accommodate our large library size and to increase 
the sensitivity of the assay, we added 20 nucleotide barcodes to the oligos by emulsion PCR 
and cloned the fragments to generate a library; in this manner, each oligo is represented by 
an average of a thousand tags within the plasmid library. Following transfection, we 
captured the GFP mRNA by hybridization and perform high-throughput sequencing of the 
UTR barcode to determine the effects of the oligos on the transcription level of the reporter 
gene. This new experimental approach decreased inter-experimental noise and allowed us to 
apply a parametric statistical framework during analysis (Supplemental Experimental 
Procedures).
 Selection of Variants Tested
For benchmarking and discovery, we first examined nearly thirty thousand SNVs within a 
set of eQTLs. We identified eQTLs from the Geuvadis RNA-seq dataset of lymphoblastoid 
cell lines (LCLs) from individuals of European (EUR) and West African (YRI) ancestry due 
to the availability of both genome sequences and immortalized cell lines for these 
individuals (Consortium, 2012; Lappalainen et al., 2013). For each of the 3,642 eQTLs, we 
designed and synthesized DNA oligonucleotides (oligos) representing the top associated 
variant and all variants in perfect LD with it. This approach selects an average of 3 SNVs per 
eQTL peak. As noted above, we expect that (i) this set will often fail to contain the true 
causal variant, and (ii) when the set does contain the causal variant, the other two variants 
will not be causal. We also included 209 eQTLs that overlapped GWAS hits for deeper 
investigation; for these, we tested all alleles in moderately strong LD (r2 >= 0.9) with the 
lead variants. After inclusion of several smaller sets of variants, and accounting for 
neighboring variants and orientation of the variant when associated with multiple genes, this 
first 79k oligo library included 39,479 oligo pairs, originating from 29,173 unique variants 
(see Supplemental Experimental Procedure for a complete breakdown).
We also performed a second MPRA experiment that assayed 264 positive control variants 
(sites identified in the first 79k MPRA library) and 3200 negative control variants. The 
negative controls included 2700 variants chosen at random across the genome matching the 
minor allele frequency distribution of the larger 79k library. To select a set of negative 
control variants with a similar biological profile, we included 500 SNVs that were in close 
proximity to an eQTL peak (within 250-1000bp) and not in LD with the lead variant. We 
incorporated all variants into a 7.5k oligo library. In total, across the two experiments we 
evaluated 85,358 oligos (42,679 reference/alternate pairs), centering the variant of interest in 
150 bp of its genomic sequence.
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 Technical Performance of MPRA
We transfected the original 79k MPRA library into two separate lymphoblastoid cell lines 
(NA12878 & NA19239) from the 1000 Genomes project as well as into a hepatocarcinoma 
cell line (HepG2). We performed eight and five technical replicates for the lymphoblastoid 
and hepatocarcinoma cell lines, respectively. We observed high coverage and excellent 
reproducibility in the assay, capturing 98.4% of the 79K oligos tested at a depth of 20 reads 
or greater. Reproducibility was excellent between experimental replicates of identical cell 
lines, with an average correlation of 0.99 (Figures 2A-B & S1), and expression values were 
strongly correlated with a traditional single-plexed luciferase assay for the 29 sequences we 
examined (R=0.84, Figure 2C).
Each oligo in our initial 79k library was captured by an average of 73 unique barcodes per 
replicate during sequencing (per sample range: 34 – 117 barcodes), with an average total 
read count of 1102 (Figure S2A). A key feature of our approach is the use of additional 
barcodes to reduce variability between replicates; reducing this variability is crucial for 
achieving the sensitivity required to detect subtle difference between alleles, since detection 
requires distinguishing the distributions for the two alleles. To evaluate how this variability 
depended on the number of barcodes, we downsampled barcodes for each oligo. We 
observed little fluctuation in the estimated mean oligo count, as long as they were captured 
with greater than 20 barcodes (Figure S2B). The variance between the individual replicates, 
on the other hand, continued to improve throughout the range from 20 to 50 barcodes, 
indicating that power to detect small differences between oligos is substantially affected by 
barcode count (Figure 2D). This effect is highlighted in the second 7.5k library: its smaller 
size allowed us to tag each oligo with an average of 350 barcodes. This resulted in a greater 
sensitivity to detect weak expression changes, illustrating the impact of the number of 
barcodes tagging each variant, and also highlighting the requirement for normalization when 
comparing between libraries (Figure S3A-D, Supplemental Experimental Procedures).
 Evaluating Regulatory Activity of the Oligos
Before looking for allelic effects, we first identified the subset of sequences for which either 
or both variants altered the expression of the reporter. Of the 29k variants evaluated in the 
original assay, 12% (3432) had an effect on the reporter for at least one of the two alleles 
(Table S1); these we call “active” sequences. Of these, 95% enhanced expression of the 
reporter (Figures 3A & S3E). Because the assay uses a weak basal promoter, it is more 
sensitive to increases in expression than to decreases. It is conceivable, however, that the 
result also reflects differences in the proportion of activating and silencing elements in the 
genome. We found that active sequences were shared between LCLs from different 
individuals more often than between different cell types (74% between NA12878 & 
NA19239 compared to 52% between NA12878 and HepG2). This difference in overlap is 
likely an underestimate, since only three replicates were performed in NA19239 compared 
to five in HepG2. The active sequences were reproducible, with the effect sizes being highly 
correlated when we re-tested 274 active variants in the 7.5k MPRA experiment (R=0.95) 
(Figure S3F).
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The sequences that scored as active in the assay are significantly enriched for markers 
associated with regulation in the genome, including open chromatin, biochemical marks 
denoting active promoters and enhancers, and individual transcription factors. We first 
evaluated overlap with open chromatin, as identified by DNase hypersensitivity sites (DHS). 
We found 43.3% of the active sequences were marked as DHS compared to only 19.4% for 
the non-active sequences, a 2.2 fold enrichment (OR=3.2, p=1.8×10-191, Figure 3B). Histone 
marks associated with active promoters and enhancers (H3k4me3, H2az, H327ac, CAGE) 
were both similarly enriched, while marks associated with heterochromatin and/or the 
blocking of transcription initiation (H3k9me3 and H3k36me3) were significantly depleted, 
as expected (Figure 3B). The strongest enrichments were seen with individual transcription 
factor (TF) binding locations, with increases ranging from 3 to 39-fold for all TFs surveyed 
in LCLs by ENCODE, except for the repressor element Ezh2. Enrichment was cell type 
specific, again as expected, with sequences active only in LCLs and not HepG2 cells being 
enriched for DHS sites in LCLs only (OR=2.2, p=6.6×10-32). Similarly, sequences that were 
active only in HepG2 cells were depleted in LCL DHS sites (OR=0.29, p=8.7×10-8) 
compared to all other sites tested (Figure 3C).
 Identifying Alleles with Differential Activity
Focusing on those sequences for which at least one allele affected the expression of the 
reporter, we identified those that showed differential expression between the reference and 
alternate allele (“allelic skew”). Of the 3432 active sequences, 842 showed allelic skew; we 
call these “expression-modulating variants” (emVars) (Table S1). Most of the emVars 
exhibited modest expression differences between alleles: only 46 had more than a 2-fold 
change (Figure 4A & B). The changes were, however, highly reproducible. We randomly 
selected 127 emVars for testing in the second, 7.5k MPRA experiment and observed strong 
correlation for allelic skew to that of the 79k experiment (R=0.97) (Figure 4C). For all 842 
emVars, the effect size was highly correlated between the two LCLs tested (R=0.92) and 
moderately correlated between LCLs and HepG2 cells (R=0.63) (Figure 4D & S4A). 
Concordant with observations that eQTLs are associated with promoter regions (Veyrieras et 
al., 2008), we saw a 13.6-fold enrichment of emVars within core promoters (+100/-50 bp) 
relative to our test set of 29k variants, and a 113.7-fold enrichment relative to all common 
variation (RR=14.8, p=2.7×10-52 & RR=113.7, p=1.2×10-121 respectively). Despite this 
enrichment, many emVars fell outside promoters, with 59% lying at a distance of 10kb or 
more from the nearest transcription start site (TSS), suggesting a prominent role for distal 
regulatory elements.
Like the overall set of active sequences, our emVars were enriched for markers associated 
with regulation such as TF binding. We therefore examined whether the presence of allelic 
skew correlated with predicted disruption of a TF motif. Of the emVars that overlapped a 
ChIP-seq peak for a given TF and that contained the corresponding TF motif, the predicted 
strength of TF binding (based on position weight matrices) differs significantly between 
alleles in 76% of cases (35 out of 46, had a difference of at least 3 in log-likelihood binding 
score based on the position weight matrices). This was 4-fold greater than the difference for 
active sequences that did not show allelic skew (OR=4.1, p=8.1×10-8) and 41-fold greater 
than for the non-active sequences (OR=42.7, p=1.9×10-36, Figure 5A). The quantitative 
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change in predicted binding also correlated with the magnitude of allelic skew observed by 
MPRA, supporting a direct relationship between predicted binding dynamics and regulatory 
activity within MPRA (R=0.47, p=6.4×10-10, Figure 5B).
We predicted that if emVars were true regulatory variants, then the allele associated with 
higher expression would also be associated with greater chromatin accessibility as measured 
by DHS in their native context. We examined emVars that were heterozygous at DHS sites in 
LCLs to see if there was an allelic skew in DHS status by counting the number of DHS reads 
attributed to each allele. We found that emVars were significantly more likely to show DHS 
skew than active sequences that were not emVars (OR=2.5, p=0.003). Furthermore, 89% of 
variants shared the same direction of effect with a strong correlation in the magnitude of 
allelic skew of the emVar activity and the number of reads at DHS sites (R=0.78, 
p=1.0×10-8, Figure 5C). We also predicted the same effect would be observed for TF-
binding as measured by ChIP-seq. We observed emVars were more likely to show allelic 
skew in the binding of at least one overlapping TF than active sequence that were not 
emVars (OR=1.9, p=0.03). For emVars that showed allelic skew in TF occupancy for at least 
one TF, there was a substantial concordance of direction and magnitude between the allelic 
skew in TF binding and the allelic skew in activity (77% agreement in directionality, 
R=0.60, p=2.1×10-7, Figure S5A & B).
 Estimating specificity of the MPRA assay—We next set out to estimate the 
specificity of the MPRA assay. Because many of the variants tested are not actually drivers 
of eQTLs, we focused on a set that is likely to be enriched: the top associated variant for 
each eQTL and all variants in perfect LD. We carried out analysis on these 11,213 variants 
from 3,642 eQTLs taking into consideration that only one, if any, of the variants in each 
region may be a true regulatory variant and only a fraction of these may drive transcriptional 
regulation discoverable by MPRA.
We observed allelic skew in activity for 27% of the active sequences associated with an EUR 
eQTL, and 26% of the YRI variants. In contrast, only 9% of the active sequences for the 
location-matched controls exhibited allelic skew, suggesting that two-thirds of the emVars 
associated with an eQTL peak are true causal variants for that peak. Randomly selected 
controls gave a similar result: 11% of active sequences contained emVars. Based on these 
results, we estimate the positive predictive value (PPV) to be 58-68%. Because the controls 
were tested independently in a second library, we were careful to normalize the tag-counts to 
match those of the first experiment. To validate our normalization, we compared the 
proportion of active sequences in the two libraries. In the second, 7.5k library, 13.4% of the 
500 location-matched and 9.7% of the 2700 randomly selected controls scored as active 
sequences, compared to 12% for the 79k library (Supplemental Experimental Procedure).
As an alternative approach to explore the false discovery rate, we compared how often the 
direction of effect agrees between MPRA and the eQTL analysis. If we focus first on those 
emVars that reside in regions biologically annotated as likely to be related to enhancer 
function (by virtue of being marked by at least two of the following; DHS, CAGE, histone 
ChIP or TF-ChIP), we find 80% agreement in directionality, corresponding to a PPV of 59% 
(R=0.61, p=7.5×10-15, Figure 5D & S5C, Supplemental Experimental Procedure). Notably, 
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when we examine sites not supported by annotation, we observe a level of agreement 
consistent with random chance (48%, R=0.06, p=0.61). When we consider all emVars 
together (regardless of whether they are annotated as related to enhancer function), the 
concordance is 67% (PPV of 34% (R=0.33, p=4.8×10-7). (We note that MPRA may not 
always correctly model the direction or magnitude of a variant's effect because the assay 
isolates a sequence from potential cofactors that may modify the effect; this has been 
observed for the genes yy1 and dorsal (Dubnicoff et al., 1997; Ip et al., 1991; Shi et al., 
1991).) Finally, we explored whether some of the discordant emVars might represent false 
eQTL discoveries by removing the weakest one-third of eQTL associations; we observed a 
further increase in agreement for annotation-supported emVars of 84%, suggesting that false 
positive eQTLs indeed contribute to the discordance.
 Estimating sensitivity of the MPRA assay—We next estimated the sensitivity of 
MPRA to identify a causal eQTL variant when it is present in our study. Based on previous 
estimates, we expect the causal allele to be in our enriched set (top eQTL variant and all 
variants in perfect LD) 34% of the time in the EUR population. Given our assay identified 
emVars in 8.6% (273/3171) of eQTL peaks, and 3-6% after accounting for false positives, 
we estimate a sensitivity of 9-18% in the EUR population. In the YRI population, lower LD 
makes it more likely that a top-scoring eQTL variant will be the causal allele, an estimated 
41%. As expected we observe a larger fraction for YRI eQTLs with 13.8% (65/471) 
containing an emVar, 5-10% after accounting for false positives, giving an estimated 
sensitivity of 12-24%. When only taking into account variants supported by functional 
annotation, the estimated sensitivity is nearly equal by virtue of an increased PPV, 
emphasizing the value of filtering MPRA emVars with existing annotations. The estimate 
that MPRA can identify the causal allele for an eQTL for 9-24% of peaks when tested is in 
line with the previous observations that 23%-64% of eQTLs are driven by promoter or 
enhancer modifications, the processes we expect MPRA to capture.
We further performed two alternate estimates for sensitivity focusing on regions where the 
causal allele is likely to be captured in our data set. We first partitioned peaks based on the 
difference in variance (Δr2) between the lead variant (the variant tested by MPRA) and the 
second strongest association. The top eQTL variant is most likely to be causal when the Δr2 
is large; accordingly we see an increase of emVars in these regions (Figure 5E). Modeling 
this relationship using a logistic regression that also controlled for the effect size of the 
eQTL, we derived a sensitivity of 16-21%. Second, we identified eQTL peaks where the 
same top associated variant occurred in both EUR and YRI. Differing LD structure between 
the two populations decreases the number of linked variants and increases the confidence 
that the top variant is causal. Of the 34 shared variants, 8 were identified as emVars, 
suggesting a 24% sensitivity of MPRA to correctly identify the causal allele when it is 
tested. Both orthogonal approaches are consistent with our initial estimate of 9-24%.
 GWAS Associated Regions
We next investigated regions previously associated with a trait or disease in human studies in 
greater depth. For 209 eQTLs overlapping 163 GWAS loci, we tested all alleles in strong LD 
(r2 > 0.9) of an eQTL variant, a total of 9664 variants. We identified 248 emVars in 99 
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eQTLs (Table S2). Based on our previous findings, we prioritized the emVars that also carry 
annotations associated with an enhancer or promoter; we identified 53 emVars in 56 eQTLs 
(a subset of these, further restricted by LD, is shown in Table 1). This represents a highly 
promising set of candidates and greatly reduced testing burden compared to current 
approaches. For example, applying only our ENCODE annotation criteria identifies 1302 
variants across 171 of the 209 eQTL peaks.
Candidates identified through MPRA still require experimental validation. We pursued a 
striking example, in a distal enhancer for prostaglandin E receptor 4 (PTGER4). The emVar 
rs9283753 sits 190 kb away from the gene and is in strong LD with the top associated risk 
allele for ankylosing spondylitis (with moderate LD to risk alleles for Crohn's disease and 
multiple sclerosis) (Figure 6A-C) (Barrett et al., 2008; Evans et al., 2011; De Jager et al., 
2009). The variant resides in a distal enhancer clearly defined by strong DHS and H3K27ac 
marks, with a CREB motif residing over rs9283753. The allele change is not predicted to 
alter binding of CREB, however, and further work will be needed to elucidate the 
mechanism of regulation.
To validate the PTGER4 emVar, we used homology-directed repair with CRISPR/Cas9 to 
perform allelic replacement. We edited two cell lines, a homozygous ancestral (NA12878) 
and a homozygous derived (NA11831) individual for the variant to test the effect of the 
allele in a controlled isogenic background. As expected from the MPRA and eQTL data, 
switching NA12878 to be homozygous for the derived allele caused an increase in 
expression for PTGER4, while the replacement with the ancestral allele decreased 
expression of NA11831 (Figure 6D-E). The concordant MPRA, eQTL and CRISPR data 
support the hypothesis that the risk allele is associated with decreased expression of 
PTGER4.
Our finding of a regulatory variant in the distal enhancer in PTGER4 is consistent with prior 
observations that identify elements outside core promoters as a significant contributor to the 
heritable component of complex diseases (Farh et al., 2015; Gjoneska et al., 2015; Parker et 
al., 2013). Looking more broadly, the 188 emVars in strong LD (r2 >= 0.9) with GWAS 
variants tend to lie further from promoters than randomly chosen eQTL variants: 78% (147) 
reside greater than 10kb from an active TSS, compared to 53% for all other emVars. We 
observed a corresponding depletion in strongly linked GWAS emVars within core promoters 
compared to all non-GWAS emVars (RR=5.3, p=0.0015).
There are many other promising candidates to pursue, including both a core promoter and 
intronic emVar in the BLK locus associated with systemic lupus erythematosus (SLE). The 
locus has previously been characterized by Guthridge and colleagues, who reported the 
promoter variant rs922483 (Guthridge et al., 2014). We replicated this finding via MPRA 
while also observing a second emVar within the first intron of the gene. This is a one base 
deletion at chr8:11353110 that introduces a novel NF-kB binding site. Notably, we found 
this emVAR decreased expression of BLK while increasing expression of the nearby gene 
FAM167A, and was validated with the traditional luciferase assay (Figure 6F-I). Moreover, 
this emVAR is in perfect LD with the top associated SLE risk variant among Europeans, 
rs2618476 (Graham et al., 2008; Guthridge et al., 2014).
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 Discussion
Our findings demonstrate that MPRA can be an invaluable tool for localizing individual 
causal variants influencing phenotypic traits. We have discovered hundreds of variants as 
putative causal alleles for gene expression, many of which are linked to known disease-
causing loci. Furthermore we directly demonstrate causality by allelic replacement of an 
ankylosing spondylitis risk allele, rs9283753, which modulates expression of PTGER4 from 
a distal enhancer.
As with any assay, it is important to understand the limitations of MPRA. The sensitivity of 
our current assay, which can identify an estimated 9-24% of the eQTL causal alleles, is 
limited in several distinct ways. (i) Causal alleles of weak effect may fall below MPRA’s 
limit of detection. (ii) Regulatory processes may require additional sequence context not 
captured on the oligo, for example, when transcription depends on nearby DNA binding co-
factor(s) or chromatin structure. (iii) Transcription repressing effects might be undetectable 
due to the low basal activity of the minimal promoter used. (iv) Causal alleles may regulate 
post-transcriptional events such as mRNA processing and stability.
The first three categories represent limitations of the current assay design and may be 
overcome in subsequent iterations of MPRA. Analysis of the proportion of active variants 
suggests that for one-third of the 79k library, we were underpowered due to a low abundance 
of the plasmid pool, something that could be overcome by increased sequencing and library 
uniformity (Figure S2C). In addition, further improvements, such as longer oligo sequences 
to capture greater contextual information and the use of a stronger constitutive promoter to 
detect repressive elements, may provide substantial gains in sensitivity. Nevertheless, there is 
undoubtedly contextual information, such as long distance interactions, that will never be 
captured by an episomal assay.
One of the largest influences to the current sensitivity is the substantial role of post-
transcriptional effects driving eQTLs; these are not targeted by our assay. For example, a 
recent analysis by Farh and colleagues of eQTL causal variants estimated that 36% of sites 
fall within transcripts themselves and only 23% are attributed to known promoter/enhancer 
elements, suggesting a substantial role for post-transcriptional activities (Farh et al., 2015). 
This implies that, at best, MPRA would have a maximum sensitivity of 23-64% for detecting 
an eQTL causal allele, since it is not designed to detect variants acting post-transcriptionally. 
In contrast, the same study reported a very different picture for autoimmunity GWAS hits: 
only 19% of causal alleles fell in transcripts and 67% resided in known promoter/enhancers, 
with the remainder associated with unannotated non-coding sequence. The discrepancy in 
the predicted mechanisms of eQTL and GWAS causal sites suggests that the sensitivity of 
MPRA may well be higher for disease-associated variants than reported here.
While the sensitivity may be increased through further technical development, the positive 
predictive value of 34-68% is likely an inherent property of the assay. This suggests that a 
substantial segment of the genome has the potential to change gene expression but is 
repressed from doing so through modulating interactions or heterochromatin silencing. 
Endogenously silenced sequences likely also explain a proportion of the active sequences we 
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observed by MPRA, which we note was unexpectedly high. As a result some variants 
discovered by MPRA will be of little biological value. However, the assay still identifies 1-2 
true causal allele for every 3 variants that score, which provides an enrichment and 
throughput unparalleled by alternative approaches. While MPRA does not prove causality it 
does substantially reduce the test space of alleles linked to a trait locus and provides a 
concise list of high priority targets for follow-up. Furthermore, the improved agreement with 
eQTL directionality when subsetting those emVars with supporting biological annotation 
demonstrates the strength of a combined approach when searching for non-coding causal 
alleles.
Regardless of the high-throughput approach taken to identify variants influencing gene 
regulation, whether it is computational or experimental, it is critical the results are 
interpreted as the product of a discovery tool and not a test for causality; a first step in the 
difficult task of linking a genetic loci to a physiological phenotype. By example, we 
demonstrate for PTGER4 how we can readily identify and validate an allele that influences 
gene expression and extending this observation further to a disease causation will require 
further work. Being able to identify and validate expression modulating variants from tens of 
thousands of sites will ultimately greatly aid in our ability to translate non-coding regulatory 
code and will bring us a step closer to the difficult task of linking human genetic variation to 
specific phenotypic traits.
 Experimental Procedures
 Variant Selection
To construct the 79k oligo library eQTLs were identified by reanalysis of the Geuvadis 
RNA-seq dataset of lymphoblastoid cell lines (LCLs) from individuals of European (EUR) 
and West African (YRI) ancestry (Supplemental Experimental Procedures). We identified 
3,642 eQTLs within EUR and YRI using significance thresholds corresponding to a 0.1% 
false positive rate within permutated samples. Using the selection and design criteria 
described in the Supplemental Experimental Procedures we selected 29,173 variants to test 
by MPRA. After accounting for both the reference and alternate alleles, neighboring variants 
and in some instances orientation of the oligo relative to the promoter we designed a total of 
78,956 oligos with the variant of interest centered within 150 bp of genomic sequence.
The 7.5k oligo library was constructed by selecting variants representing four different 
classes. (i) Variants called as expression positive in the 79k oligo experiment. (ii) Variants 
called as expression positive and having allelic skew (emVars) in the 79k oligo experiment. 
(iii) Location matched controls, selected for being between 250-1000 bp of a lead eQTL 
association, not in LD with the lead candidate (r2 <= 0.25) and not having an appreciable 
eQTL signal in the Geuvadis or GTEx datasets. (iv) Randomly selected variants from across 
the genome matching only to the minor allele frequency spectrum of EUR eQTL variants. A 
subset of the randomly selected variants were further filtered for having no detectable eQTL 
signal in the Geuvadis and GTEx datasets. The two sets of randomly selected sites behaved 
similarly by MPRA and were combined as a single set during analysis.
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 Massively Parallel Reporter Assay
Oligos were synthesized (Agilent Technologies) as 180 bp sequences containing 150 bp of 
genomics sequence and 15 bp of adapter sequence on either end. Unique 20 bp barcodes 
were added by emulsion PCR along with additional constant sequence for subsequent 
incorporation into a backbone vector by gibson assembly. The oligo library was expanded by 
electroporation into E.coli and the resulting plasmid library was sequenced by Illumina 
2×150 bp chemistry to acquire barcode/oligo pairings. The library underwent restriction 
digest and GFP with a minimal TATA promoter was inserted by gibson assembly resulting in 
the 150 bp oligo sequence positioned directly upstream of the promoter and the 20 bp 
barcode falling in the 3′ UTR of GFP. After expansion within E.coli the final MPRA plasmid 
library was sequenced by Illumina 1×30 bp chemistry to acquire a baseline representation of 
each oligo within the library.
Libraries were electroporated into LCLs using the Neon system (Life Technologies). We 
performed multiple independent replicates for NA12878 (5 replicates) and NA19239 (3 
replicates) with each replicate consisting of ∼5×108 cells. Transfections for 5 independent 
replicates of HepG2 cells were performed using Lipofectamine 3000 (Life Technologies). 
For both cell types RNA was harvested 24 hours post transfection followed by DNA 
digestion, capturing of the GFP transcripts and cDNA synthesis. Sequencing libraries were 
constructed by adding adapters by PCR and sequenced using Illumina 1×30 bp chemistry. 
Detailed experimental conditions as well as oligo and primer sequences are provided in the 
Supplemental Experimental Procedures.
 Allelic Replacement at PTGER4 Locus
Cas9-GFP vector, guide RNA (gRNA) targeting rs9283753, and a 150 bp homology oligo 
with either the reference (C) or alternate (T) allele, were transfected into 5×106 LCLs. Cells 
were sorted for GFP expression 24 hours post-transfection and expanded for two week in 
bulk. Single cell dilutions of each bulk population were performed and after two weeks of 
growth genotyped using Illumina sequencing to identify mutations of interest. All clones 
were confirmed by Sanger sequencing. To quantify changes in expression of PTGER4 qPCR 
was performed on clonal colonies identified as either HDR or wild-type. RNA was collected 
from ∼7.5×10ˆ6 cells, and cDNA was synthesized. qPCR was performed with technical 
triplicates for each reaction. Detailed transfection and qPCR conditions as well as gRNA, 
homology oligo and primer sequences are provided in the Supplemental Experimental 
Procedures.
 Data Analysis
The sum of the barcode counts for each oligo within replicates were normalized and oligos 
showing differential expression relative to the plasmid input were identified by modeling a 
negative binomial with DESeq2 and applying a threshold of 0.01 for the Bonferroni 
corrected p-value. For sequences that displayed regulatory activity we tested if the reference 
and alternate allele showed similar activity by applying a t-test on the log transformed RNA/
plasmid ratios for each experimental replicates (Figures S4B-E). Combining independent 
results from NA12878 and NA9239 using Fisher's method generated a final LCL specific 
call set. We used an FDR (Benjamini–Hochberg) cutoff of 5% as a threshold for calling 
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emVars. Detailed procedures for calculating enrichments, sensitivity/specificity and 
concordance with established measures of regulatory activity are provided in the 
Supplemental Experimental Procedures.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overview of the MPRA workflow
(A) Oligos are synthesized as 180 mers followed by cleavage off of the array. (B) The 
ssDNA is amplified, barcoded and converted to dsDNA by emulsion PCR which is then 
cloned into a reporter vector which has had the reporter gene removed to create the 
mpra:Δorf library (C). The plasmid library is linearized between the barcode and oligo 
sequence by restriction digest and a minimal promoter and GFP open reading frame is 
inserted by gibson assembly to create the final mpra:gfp library (D) which is used for 
transfection into the desired cell type (E). RNA is harvested from the transfected cells, 
mRNA is captured, sequenced (F) and barcode counts are compared to the count estimates 
from the sequencing of the mpra:orf library (D).
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Figure 2. Experimental reproducibility
(A) Correlation of normalized oligo counts between two transfection replicates of NA12878. 
(B) Average normalized oligo counts for all five plasmid replicates compared to normalized 
counts for the five replicates from NA12878 RNA. Axis across all plots were kept constant 
with subplots added when additional datapoint were excluded from the main plot (A & B). 
Blue boxes within the inserts signify the displayed area of the main plots. (C) Luciferase 
assay validation of estimated effect sizes for individual oligos tested by MPRA. Each point 
represents the average of 8 MPRA and 4 qPCR replicates. qPCR values were normalized to 
two non-significant sequences (green points) as determined by MPRA. Blue points: 
significantly expressed sequences from MPRA; cyan point: marginally significant sequence. 
Correlation is provided as Pearson's R. (D) Coefficient of variation between experimental 
replicates as a product of the number of barcodes tagging an oligo.
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Figure 3. Validation of expression modifying sequences discovered by MPRA
(A) Distribution of effect sizes (log2 of the RNA/plasmid ratio) for oligos that were detected 
as being under or over expressed. (B) Log2(odds ratio) for the enrichment of regulatory 
annotations in the 3432 MPRA active sequences within LCLs relative to non-active 
sequences. (C) Log2(odds ratio) for the enrichment in LCL DHS sites for active sequences 
shared between LCLs and HepG2s (blue), active in only LCLs (red) and active in only 
HepG2 cells (green). Asterisk: fisher's test p-value < 0.01.
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Figure 4. Expression-modulating variant (emVar) reproducibility and effect size distribution
(A) Distribution of expression strength (x-axis) and allelic skew (y-axis) for all 29k variants. 
(B) Cumulative distribution of the absolute difference of the log2 fold change between the 
reference and alternate allele for emVars (blue), expression positive variants that were not 
detected as emVars (green) and all other variants (red). (C) Allelic skew as measured by 
MPRA for 127 positive controls values discovered in the original 79k library (x-axis) that 
were tested in the 7.5k library (y-axis). (D) Comparison of allelic skew as estimated from 
the mean of 2 independent LCLs (NA12878 & NA19239). Red points in both plots denote 
variants called as emVars from the joint LCL analysis. Correlation is provided as Pearson's 
R.
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Figure 5. emVar concordance with existing measures of allelic effect
(A) Proportion of variants by their MPRA classification that fall in an ENCODE 
transcription factor (TF) ChIP-seq peak and contain the predicted motif. Variants are binned 
according to the difference in predicted binding strength between the two alleles. (For 
multiple TF associations, the one with the largest delta is used). (B) MPRA skew estimates 
for LCL emVars with TF motif/ChIP annotations compared to the predicted change in 
binding between the two alleles. (C) Comparison between skew seen in MPRA and that in 
DHS for all emVars passing stringent filters for high-confidence DHS skew sites (methods). 
Skew is calculated as log2(Alt-allele counts / Ref-allele counts). (D) Overlap between 
annotation-positive sites (methods), sequences detected as regulatory by MPRA and emVars. 
(E) Proportion of EUR eQTLs explained by an emVar plotted against the difference in 
variance explained between the top variant and the second strongest association in the EUR 
eQTL analysis. grey line: all emVars, solid red line: annotation positive emVars, dashed red 
line: annotation negative emVars. All Correlations are provided as Pearson’s R.
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Figure 6. emVars associated with ankylosing spondylitis and systemic lupus erythematosus
(A) Plot of the PTGER4 locus which overlaps a GWAS peak for ankylosing spondylitis 
displaying ChIA-PET and ENCODE annotations (top 6 tracks), observed allelic skew (track 
7) and expression strength (track 8) from MPRA. Significant variants for expression (blue) 
and skew (red) in the MPRA data indicated by color; black: non-significant. (B) MPRA 
expression values of the PTGER4 variant rs9283753 in LCL's normalized to the plasmid 
library. (C) LCL eQTL results in EUR and YRI populations for the PTGER4 with 
rs9283753. (D & E) PTGER4 expression as measured by qPCR for two LCL's that 
underwent allelic replacement at rs9283753. (F) Plot of the FAM167A-BLK locus 
associated with systemic lupus erythematosus. (G) MPRA expression values of the 
chr8:11353110 deletion variant in LCL's normalized to the plasmid library. (H & I) LCL 
eQTL results in EUR and YRI populations for the FAM167A and BLK associations.
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